ASSESSMENT OF INDUCED SPUTUM AS A TOOL TO EVALUATE ANTI-INFLAMMATORY AGENTS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。为了确定用高渗盐水诱导的痰中中性粒细胞、活性弹力酶和细胞因子是否是有用的筛查试验，以确定具有已知抗炎特性的特定药物是否适合进行更广泛的临床试验。这一目标将通过一种抗炎药布洛芬和一种抗炎药塞来昔布来实现，布洛芬已被证明对CF具有临床益处，塞来昔布可能对CF具有临床益处。另设不治疗组作为对照组。对于临床稳定的CF患者，将在治疗前(基准期)、治疗期(治疗期)和恢复期(恢复期)之前(基准期)和之后(恢复期)对诱导痰标本的结果进行评估。变化将在每个手臂内和手臂之间进行评估。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine whether neutrophils, active elastase, and cytokines measured in sputum induced using hypertonic saline are useful screening tests for determining if a particular agent with known anti-inflammatory properties is a suitable candidate for more extensive clinical trials in patients with CF. This aim will be addressed using one anti-inflammatory agent, ibuprofen, that has been shown to have clinical benefit in CF, and one anti-inflammatory agent, celecoxib, that has potential to have clinical benefit in CF. A ¿no treatment¿ arm will be included as the control group. The outcome measures will be assessed in induced sputum specimens before (Baseline Period), during (Treatment Period), and after (recovery Period) a 4-week treatment period in clinically stable CF patients. Changes will be assessed within each arm and between arms.